Leki na otyłość w leczeniu stłuszczenia wątroby?

Added: 2026-05-20

GLP-1 receptor agonists like semaglutide may offer therapeutic benefits for metabolic dysfunction-associated steatohepatitis (MASH), with clinical trials showing approximately 62.9% of patients experienced resolution of MASH without worsening liver fibrosis, alongside an average 10.5% reduction in body weight, suggesting these medications could address both obesity and liver disease simultaneously.